Abstracts Archive - Page 550 of 1683 - ATC Abstracts

2020 American Transplant Congress
Changes in Health-Related Quality of Life During the First Year in Lung Transplantation Recipients
H. Zhou, J. Chen
Lung Transplant Center, Wuxi People’s Hospital, Wuxi, China
*Purpose: This longitudinal study was conducted to recognize the tracks of HRQOL during the first year after transplantation and the main factors associated with HRQOL…
2020 American Transplant Congress
Predominant Role of Microvascular Injury and Rarefaction Function as Drivers of Progressive Renal Damage and Fibrosis Post Mild and Severe Acute Ischemia-Reperfusion Injury
S. Lan¹, B. Yang¹, J. Sabo-Vatasescu², M. Bourgault², A. Karakeussian-Rimbaud³, J. Turgeon³, S. Qi¹, N. Patey⁴, M. Dieudé⁵, M. Hébert¹
¹Medicine Faculty, CRCHUM, CDTRP, University of Montreal, Montreal, QC, Canada, ²CRCHUM, Montreal, QC, Canada, ³CRCHUM, CDTRP, Montreal, QC, Canada, ⁴Medicine Faculty, CRCHUM, Saint Justine Hospital, University of Montreal, Montreal, QC, Canada, ⁵CRCHUM, CDTRP, University of Montreal, Montreal, QC, Canada
*Purpose: Ischemia-reperfusion injury (IRI) is a major risk factor for chronic renal failure. Here, we characterize the different cell deaths in tubular and microvascular compartments…
2020 American Transplant Congress
Identification of Novel Gene Targets Inducing Resistance in Liver Ischemia Reperfusion Injury by CRISPR Screening
C. Kuscu, A. R. Wolen, C. Kuscu, C. Watkins, A. Bajwa, J. D. Eason, D. Maluf, V. Mas
Dept of Surgery, Transplant Research Institute, James D. Eason Transplant Institute, University of Tennessee Health Science Center, Memphis, TN
*Purpose: Liver transplantation (LT) is the best treatment option for patients with end-stage liver disease (ESLD). However, the gap between available donors and recipients in…
2020 American Transplant Congress
Gasdermin-D Mutation is Protective against Renal Ischemia Reperfusion Injury
J. Li, N. Rogers, S. Alexander
Centre for Transplant and Renal Research, Westmead Institute for Medical Research, Westmead, Australia
*Purpose: Pyroptosis, a pro-inflammatory form of cell death, is dependent on membrane pore formation through the assembly of cleaved Gasdermin-D molecules. We hypothesized that this…
2020 American Transplant Congress
Kidneys from AKI Donors with Poor Long-Term Outcomes Present an Impaired Protein Expression for Cellular Stress and Repair
F. Neri¹, M. Lo Faro¹, C. Boffa¹, T. Surik¹, M. Kaisar¹, E. J. Sharples², J. P. Hunter¹, J. Lindeman³, R. Ploeg¹
¹Nuffield Department of Surgical Sciences, Oxford University, Oxford, United Kingdom, ²Oxford Transplant Centre, Oxford, United Kingdom, ³Department of Vascular Surgery, Leiden University Medical Center (LUMC), Leiden, Netherlands
*Purpose: The utilization of kidneys from donors with acute kidney injury (AKI) is often limited by unpredictable post-transplantation outcomes. The aim of our study was…
2020 American Transplant Congress
Factors Associated with Renal Graft Loss in Simultaneous Kidney-Heart Transplant Recipients in the UNOS Cohort
K. A. Agarwal¹, H. Patel¹, K. Almonte², F. Cardarelli¹, N. Agrawal¹
¹Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, ²Medicine, Mount Auburn Hospital, Cambridge, MA
*Purpose: Simultaneous kidney and heart transplants (SKHT) are employed for patients with both end-stage heart failure and severely impaired kidney function. Renal outcomes in such…
2020 American Transplant Congress
Survival of ESRD Patients with an EPTS > 90% Listed for Kidney Transplant
M. S. Sampaio¹, E. Lum¹, P. Homkrailas¹, G. Danovitch¹, H. Gritsch², S. Bunnapradist¹
¹UCLA - Division of Nephrology, Los Angeles, CA, ²UCLA - Division of Urology, Los Angeles, CA
*Purpose: Mortality on the kidney transplant waitlist is high especially in candidates with a high Estimated Post Transplant Survival (EPTS) score. We examined outcomes of…
2020 American Transplant Congress
Uromodulin to Osteopontin Ratio in Deceased Donor Urine is Associated with Kidney Graft Outcomes
S. G. Mansour¹, C. Liu², Y. Jia², P. Reese³, I. Hall⁴, T. El-Achkar⁵, K. LaFavers⁵, W. Obeid², M. Thangamani⁶, A. Rosenberg², M. Doshi⁷, E. Akalin⁸, J. Bromberg⁹, M. Harhay¹⁰, S. Mohan¹¹, B. Schröppel¹², P. Daneshpajouhnejad², P. Singh¹³, F. Weng¹⁴, H. Thiessen-Philbrook², C. Parikh²
¹Yale, New Haven, CT, ²Johns Hopkins, Baltimore, MD, ³UPenn, Philadelphia, PA, ⁴Univ of Utah, Salt Lake City, UT, ⁵Indiana Univ, Bloomington, IN, ⁶Cornell, New York, NY, ⁷Univ of Michigan, Ann Arbor, MI, ⁸Montefiore, Bronx, NY, ⁹Univ of Maryland, College Park, MD, ¹⁰Drexel, Philadelphia, PA, ¹¹Columbia, NY, NY, ¹²Univ Hosp, Ulm, Germany, ¹³Thomas Jefferson, Philadelphia, PA, ¹⁴St. Barnabas, Livingston, NJ
*Purpose: Deceased-donor kidneys often experience extensive injury, activating adaptive and maladaptive pathways. While these adaptive and maladaptive mechanisms are initiated in donor kidneys prior to…
2020 American Transplant Congress
TRANSBIO Study: Clinical Evaluation of Immunobiogram, a Novel In Vitro Diagnostic Immunoassay to Guide Adjustment of Immunosuppressive Therapy in Kidney Transplantation
J. Pascual¹, C. Jiménez², M. Krajewska³, C. Kotton⁴, D. Seron⁵, J. Portolés⁶, O. Witzke⁷, S. S. Sorensen⁸, A. Andrés⁹, T. Díez¹⁰, A. Ortega¹⁰, I. Portero¹⁰
¹Consorci Mar Parc de Salut, Barcelona, Spain, ²La Paz Hospital, Madrid, Spain, ³Wroclaw Medical University, Wroclaw, Poland, ⁴Massachusetts General Hospital, Boston, MA, ⁵Vall d’Hebron Hospital, Barcelona, Spain, ⁶Puerta de Hierro Mahadahonda Hospital, Madrid, Spain, ⁷University Hospital Essen, University Duisburg-Essen, Essen, Germany, ⁸Rigshospitalet, Copenhagen, Denmark, ⁹12 de Octubre Hospital, Madrid, Spain, ¹⁰Biohope Scientific Solutions for Human Health SL, Madrid, Spain
*Purpose: Immunobiogram (IMBG) is a first-in-class blood-based pharmacodynamic immunoassay that provides the sensitivity/resistance profile of each patient’s lymphocytes to a panel of immunosuppressive drugs (IS).…
2020 American Transplant Congress
Identification of the dnDSA Inducing HLA Mismatches Across Multiple Renal Transplant Centers: A 3-Year Longitudinal Analysis of >11,000 HLA Mismatches in 2271 Patients
J. M. Brennan¹, M. D. Stegall², C. A. Schinstock², R. L. Heilman³, L. M. Rebellato⁴, M. D. Samaniego-Picota⁵, D. Lesser⁴, M. J. Ghandi², J. L. Beaumont¹, M. J. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Phoenix, AZ, ⁴East Carolina University, Greenville, NC, ⁵Henry Ford Transplant Institute, Detroit, MI
*Purpose: The presence of a mismatch (MM) between donor and recipient HLA does not always lead to the patient developing a de novo donor-specific anti-HLA…